Assessment of Cancer Therapy Evaluation Program Advocacy and Inclusion Rates of People Living With HIV in Anti–PD1/PDL1 Clinical Trials

Authors:

Abstract
The advent of highly active antiretroviral therapy (ART) has revolutionized the treatment of people living with HIV (PLWH), with many expected to have a nearly normal life expectancy.1 Furthermore, the proportion of PLWH in the US aged 65 years or older is projected to increase from 8.5% in 2010 to 21.4% by 2030.2 Cancer is now a leading cause of morbidity and mortality in this population,3 with non–AIDS-defining cancers, such as lung and colon cancer, becoming increasingly prevalent.2,4

This publication has 19 references indexed in Scilit: